Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 11Phase 1 8Phase NA 4Phase 2/3 3Phase 1/2 3Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 2Successful Conversion Rate of Operation 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

olaparib 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4fludarabine 3X-Rays 2Taxes 2Platinum 2Paclitaxel 2Oncolytic Virotherapy 2Letrozole 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytoreduction Surgical Procedures 2Cisplatin 2Carboplatin 2Aspirin 21,2-diaminocyclohexaneplatinum II citrate 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1pertuzumab 1pembrolizumab 1palbociclib 1niraparib 1montelukast 1gallium 68 PSMA-11 1eribulin 1entrectinib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ovarian Neoplasms × Drug Therapy × Clear all
NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
15 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡